Illumina Inc. is a standout player in the oncology stocks market, as highlighted in our recent article on the Top 10 Oncology Stocks to Buy Now. The company has been making waves, with TD Cowen recently raising its price target on ILMN to $140 from $115 while maintaining a Hold rating. This adjustment came as part of the company’s outlook for the life science tools industry in the fourth quarter.
Despite cautious advice from several firms for 2026, analysts are optimistic about Illumina’s potential for next year. Recent share price increases have raised expectations, leaving room for upside in the coming months. Illumina is well-poised to capitalize on the growing demand for advanced genomic sequencing and multiomics solutions in the field of precision oncology research.
In a separate development, Illumina Inc. launched Illumina Connected Multiomics, a cloud-based platform aimed at integrating and analyzing large multiomic datasets. This move further solidifies Illumina’s position as a leader in oncology-focused genomic innovation.
The company’s AI-driven platforms have been instrumental in accelerating cancer diagnostics, drug development, and personalized treatment strategies. Illumina’s commitment to advancing genomic technology has positioned it as a key player in the fight against cancer.
While Illumina Inc. shows promise as an investment opportunity, there are other AI stocks that offer greater upside potential and lower downside risk. For investors seeking undervalued AI stocks with significant growth potential, exploring alternative options may be beneficial.
For more investment insights and stock recommendations, be sure to check out our free report on the best short-term AI stock. Stay informed about the latest trends and opportunities in the market by following our coverage on the 12 Best Multibagger Stocks to Buy Heading into 2026 and the 7 Best Rising Tech Stocks to Buy Now.
Disclosure: None.
